Holen Sie sich die Stockscreener-App
0.617
0.00%
0.00
Handel nachbörslich:
.62
0.003
+0.49%
Schlusskurs vom Vortag:
$0.617
Offen:
$0.6047
24-Stunden-Volumen:
352.50K
Relative Volume:
0.05
Marktkapitalisierung:
$31.96M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-563.30K
KGV:
-3.0912
EPS:
-0.1996
Netto-Cashflow:
$-22.23M
1W Leistung:
-1.75%
1M Leistung:
+40.20%
6M Leistung:
-31.44%
1J Leistung:
-50.64%
1-Tages-Spanne:
$0.60
$0.649
1-Wochen-Bereich:
$0.59
$0.73
52-Wochen-Spanne:
$0.38
$1.59
Promis Neurosciences Inc Stock (PMN) Company Profile
Firmenname
Promis Neurosciences Inc
Sektor
Branche
Telefon
416-847-6898
Adresse
SUITE 200, 1920 YONGE STREET, TORONTO
Vergleichen Sie PMN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
0.617 | 20.17M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.88 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.87 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.91 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
661.32 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
319.32 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Promis Neurosciences Inc Aktie (PMN) Neueste Nachrichten
ProMIS Neurosciences Reports Increased R&D Expenses and Net Loss - MSN
Traders Consider Averaging Down in ProMIS Neurosciences Inc.2025 Fundamental Recap & Weekly High Conviction Trade Ideas - beatles.ru
Why ProMIS Neurosciences Inc. stock attracts strong analyst attentionJuly 2025 Pullbacks & High Win Rate Trade Tips - thegnnews.com
Market reaction to ProMIS Neurosciences Inc.’s recent newsStop Loss & Weekly Sector Rotation Insights - Newser
ProMIS Neurosciences: Promising Alzheimer's Treatment and Strong Financials Drive Buy Rating - AInvest
What makes ProMIS Neurosciences Inc. stock price move sharplyPortfolio Performance Summary & Free Long-Term Investment Growth Plans - Newser
ProMIS Neurosciences Inc. Building a Base Near Support2025 Market Sentiment & Safe Entry Momentum Tips - kangso.co.kr
Combining price and volume data for ProMIS Neurosciences Inc.July 2025 Action & Free Growth Oriented Trading Recommendations - Newser
Multi asset correlation models including ProMIS Neurosciences Inc.2025 Trade Ideas & Smart Swing Trading Techniques - Newser
ProMIS Neurosciences Reports Q2 2025 Financial Results, Receives FDA Fast Track Designation for PMN310. - AInvest
Leading vs lagging indicators on ProMIS Neurosciences Inc. performance2025 Trading Recap & Free Daily Entry Point Trade Alerts - Newser
ProMIS Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
ProMIS Neurosciences' Strategic Capital Raise and Long-Term Growth Potential - AInvest
Is ProMIS Neurosciences Inc. stock ready for a breakoutJuly 2025 Outlook & Intraday High Probability Setup Alerts - Newser
ProMIS Neurosciences: Navigating Capital-Intensive Risks for a Potential Alzheimer's Breakthrough - AInvest
ProMIS Neurosciences Reports Q2 GAAP EPS of -$0.29, Cash and Cash Equivalents at $4.5 Million - AInvest
ProMIS Neurosciences Inc. stock trend outlook and recovery pathJuly 2025 Price Swings & Weekly Hot Stock Watchlists - Newser
ProMIS Neurosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Chart overlay techniques for tracking ProMIS Neurosciences Inc.Weekly Trend Summary & High Accuracy Trade Signal Alerts - Newser
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights - Ariva
Published on: 2025-08-13 07:52:02 - Newser
ProMIS Neurosciences Q2 2025 Financial Results & Corporate Highlights - TradingView
ProMIS Neurosciences Inc. SEC 10-Q Report - TradingView
ProMIS Neurosciences receives FDA Fast Track designation for PMN310 in Alzheimer's disease. - AInvest
ProMIS Neurosciences Announces Q2 2025 Financial Results & Corporate Highlights: FDA Grants Fast Track Designation for PMN310 in Alzheimer’s Disease, PRECISE-AD Trial Progresses on Schedule, and Secures $21.6 Million in Gross Proceeds. - AInvest
Analyzing recovery setups for ProMIS Neurosciences Inc. investorsJuly 2025 Analyst Calls & Weekly Stock Breakout Alerts - Newser
Multi factor analysis applied to ProMIS Neurosciences Inc.Dividend Hike & Daily Entry Point Trade Alerts - Newser
Institutional scanner results for ProMIS Neurosciences Inc.Free Swing Setup With Technical Confirmation - Newser
ProMIS Neurosciences PMN 2025Q2 Earnings Preview Upside Ahead on Chinese Market Expansion - AInvest
Key metrics from ProMIS Neurosciences Inc.’s quarterly dataSwing Watchlist With Tight Stop Placement - Newser
Should I buy ProMIS Neurosciences Inc. stock before earningsFree Daily Top Performing Stock Insights - Newser
ProMIS Neurosciences Inc. stock momentum explainedPortfolio Building Plan and Summary Guide - Newser
Will ProMIS Neurosciences Inc. stock recover after recent dropTrade Safety Report with Pattern Insights - Newser
ProMIS Neurosciences Inc. stock daily chart insightsEntry Opportunity Screener with Confirmation - Newser
Is ProMIS Neurosciences Inc. forming a reversal patternSector-Wise Stock Strength Trend Analysis - Newser
Can swing trading help recover from ProMIS Neurosciences Inc. lossesStock Forecast Tools for Retail Traders - Newser
Intraday pattern recognizer results for ProMIS Neurosciences Inc.Momentum Trend Signal Weekly Recap Summary - Newser
How ProMIS Neurosciences Inc. stock performs during market volatilityBuy Strategy with Smart Exit Timing - Newser
PMN’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Promis Neurosciences (PMN) Expected to Announce Quarterly Earnings on Thursday - Defense World
Finanzdaten der Promis Neurosciences Inc-Aktie (PMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Promis Neurosciences Inc-Aktie (PMN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Shafmaster Madge K. | Director |
Sep 24 '24 |
Buy |
1.30 |
70,000 |
91,028 |
208,333 |
| Shafmaster Madge K. | Director |
Sep 23 '24 |
Buy |
1.28 |
70,000 |
89,656 |
138,333 |
| Shafmaster Madge K. | Director |
Sep 20 '24 |
Buy |
1.25 |
60,000 |
75,066 |
68,333 |
| GORDON MICHAEL S | 10% Owner |
Sep 16 '24 |
Buy |
1.22 |
76,931 |
94,071 |
76,931 |
| GORDON MICHAEL S | 10% Owner |
Sep 17 '24 |
Buy |
1.40 |
16,292 |
22,809 |
93,223 |
1.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):